Anti-Human Bcl-2 (NT)
| Code | Size | Price |
|---|
| LEI-B446-20ug | 20 ug | £199.00 |
Quantity:
| LEI-B446-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:B472
Long Description:
Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer.2 Bcl-2 is the founding member of a family of over 20 proteins that are critical regulators of apoptosis.2,3 These can be divided into two classes: those that inhibit apoptosis and those that promote cell death. Bcl-2 is an inner mitochondrial membrane protein that inhibits apoptosis.4 It is thought to act by interacting with pro-apoptotic Bcl-2 family members such as Bak and Bad.5 Overexpression of Bcl-2 has been linked to human cancers such as B-cell lymphoma and prostate cancer.4,6
Target:
Bcl-2
References
1. Lockshin, RA. et al. (2000) Cell Death Differ. 7:2-7. 2. Cory, S. et al. (2003) Oncogene 22:8590-607. 3. Heiser, D. et al. (2004) Exp. Geron. 39:1125-35. 4. Hockenbery, D. et al. (1990) Nature 348:334-6.
Related Products
| Product Name | Product Code | Supplier | Anti-Human Bcl-2 (Intermediate Domain) | LEI-B445 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bcl-2 (Intermediate Domain) Blocking Peptide | LEI-B471 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bcl-2 (NT) Blocking Peptide | LEI-B472 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||